The American Journal of Medicine
Volume 121, Issue 12 , Pages 1065-1071 , December 2008

Impact of Changing Definitions for Myocardial Infarction: A Report from the AMIS Registry

  • Philip Urban, MD

      Affiliations

    • Cardiovascular Department, La Tour Hospital, Geneva, Switzerland
    • Corresponding Author InformationRequests for reprints should be addressed to Philip Urban, MD, Cardiovascular Department, La Tour Hospital, 1 Av JD Maillard, Geneva 1217, Switzerland
    • ,
  • Dragana Radovanovic, MD

      Affiliations

    • AMIS Plus Data Center, Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
    • ,
  • Paul Erne, MD

      Affiliations

    • Cardiology Department, Cantonal Hospital, Luzern, Switzerland
    • ,
  • Jean-Christophe Stauffer, MD

      Affiliations

    • Cardiology Center, Cantonal Hospital, Fribourg, Switzerland
    • ,
  • Giovanni Pedrazzini, MD

      Affiliations

    • Cardiocentro, Lugano, Switzerland
    • ,
  • Stephan Windecker, MD

      Affiliations

    • Cardiology Department, Inselspital, Bern, Switzerland
    • ,
  • Osmund Bertel, MD

      Affiliations

    • Cardio-Vascular Center Zurich, Klinik im Park, Zurich, Switzerland
    • ,
  • AMIS Plus investigators

References 

  1. WHO MONICA Project (Myocardial infarction and coronary deaths in the World Health Organization MONICA project). Circulation. 1994;90:583–612
  2. Thiemann DR, Coresh J, Oetgen WJ, Powe NR. The association between hospital volume and survival after acute myocardial infarction in elderly patients. N Engl J Med. 1999;340:1640–1648
  3. Juul-Möller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet. 1992;340:1421–1425
  4. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993) (Observations from the National Registry of Myocardial Infarction). Circulation. 1994;90:2103–2114
  5. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol. 2000;36:959–969
  6. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50:2173–2195
  7. Roger VL, Killian JM, Weston SA, et al. Redefinition of myocardial infarction: prospective evaluation in the community. Circulation. 2006;114:790–797
  8. Salomaa V, Koukkunen H, Ketonen M, et al. A new definition for myocardial infarction: what difference does it make?. Eur Heart J. 2005;26:1719–1725
  9. Erne P, Radovanovic D, Urban P, et al. Early drug therapy and in-hospital mortality following acute myocardial infarction. Heart Drug. 2003;3:134–140
  10. Fassa A-A, Urban P, Radovanovic D, et al. Trends in reperfusion therapy of ST elevation myocardial infarction in Switzerland: six year results from a nationwide registry. Heart. 2005;91:882–888
  11. Radovanovic D, Erne P, Urban P, et al. Gender differences in management and outcome in patients with acute coronary syndromes: results on 20290 patients from the AMIS Plus registry. Heart. 2007;93:1369–1375
  12. Schoenenberger AG, Radovanovic D, Stauffer J-C, et al. Age-related differences in the use of guideline-recommended medical and interventional therapies for acute coronary syndromes: a cohort study. J Am Geriatr Soc. 2008;56:510–516
  13. Berger A, Stauffer JC, Radovanovic D, et al. Comparison of in-hospital mortality for acute myocardial infarction in Switzerland with admission during routine duty hours versus admission during out of hours (insight into the AMIS Plus Registry). Am J Cardiol. 2008;101:422–427
  14. Apple FS, Jesse RL, Newby K, Wu AHB, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem. 2007;53:547–551
  15. Tzivoni D, Koukoui D, Guetta V, et al. Comparison of troponin T to creatinine kinase and to radionuclide cardiac imaging infarct size in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Am J Cardiol. 2008;101:753–757
  16. Hasdai D, Behar S, Boyko V, et al. Cardiac biomarkers and acute coronary syndromes—the Euro Heart Survey of Acute coronary syndromes experience. Eur Heart J. 2003;24:1189–1194
  17. Salomaa V, Ketonen M, Koukkunen H, et al. The effect of correcting for troponin on trends in conorary heart disease events in Finland during 1993-2002: the FINAMI study. Eur Heart J. 2006;27:2394–2399
  18. French JK, White HD. Clinical implications of the new definition of myocardial infarction. Heart. 2000;90:99–106
  19. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial (Randomized Intervention Trial of unstable Angina). Lancet. 2002;360:743–751
  20. Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. Circulation. 2000;102:1216–1220
  21. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med. 1992;327:146–150
  22. James S, Armstrong P, Califf R, et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med. 2003;115:241–244
  23. Sabatine DS, Morrow DA, De Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760–1766

 Funding: The AMIS Plus registry is funded by unrestricted grants from the Swiss Heart Foundation and from Abbott, Astra-Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Essex/MSD, GlaxoSmithKline, Guidant, INVATEC, Johnson & Johnson – Cordis Division, A Menarini, Medtronic, Mepha Pharma, Merck Sharp & Dohme-Chibret, Novartis, Pfizer, Sanofi-Aventis, Schering, Servier, SPSS, St. Jude Medical, and Takeda Pharma, all in Switzerland.

 Conflict of interest: none.

PII: S0002-9343(08)00843-7

doi: 10.1016/j.amjmed.2008.08.020

The American Journal of Medicine
Volume 121, Issue 12 , Pages 1065-1071 , December 2008

Article Tools

* Image Usage & Resolution